Track topics on Twitter Track topics that are important to you
A phase 2/3 study compared two combination approaches with azacitidine and concluded that azacitidine alone showed similar efficacy to either combo for patients with high-risk MDS. So what's next in MDS management?
Medscape Medical News
Original Article: Azacitidine Still Standard of Care in High-Risk MDSNEXT ARTICLE